Toll Free: 1-888-928-9744

OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the OncoMed Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OncoMed Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of OncoMed Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of OncoMed Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the OncoMed Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate OncoMed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of OncoMed Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the OncoMed Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of OncoMed Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of OncoMed Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of OncoMed Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
OncoMed Pharmaceuticals, Inc. Snapshot 5
OncoMed Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
OncoMed Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
OncoMed Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
OncoMed Pharmaceuticals, Inc. - Pipeline Products Glance 13
OncoMed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
OncoMed Pharmaceuticals, Inc. - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
OncoMed Pharmaceuticals, Inc. - Drug Profiles 17
demcizumab 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
tarextumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ipafricept 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
OMP-52M51 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
vantictumab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
OMP-305B83 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Biologic for Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Biologic to Inhibit Wnt Pathway for Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody to Inhibit Other Pathways for Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
OMP-131R10 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OncoMed Pharmaceuticals, Inc. - Pipeline Analysis 34
OncoMed Pharmaceuticals, Inc. - Pipeline Products by Target 34
OncoMed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 35
OncoMed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 36
OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 37
OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates 38
OncoMed Pharmaceuticals, Inc. - Dormant Projects 49
OncoMed Pharmaceuticals, Inc. - Locations And Subsidiaries 50
Head Office 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52
List of Tables
OncoMed Pharmaceuticals, Inc., Key Information 5
OncoMed Pharmaceuticals, Inc., Key Facts 5
OncoMed Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
OncoMed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
OncoMed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
OncoMed Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11
OncoMed Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
OncoMed Pharmaceuticals, Inc. - Phase II, 2014 13
OncoMed Pharmaceuticals, Inc. - Phase I, 2014 14
OncoMed Pharmaceuticals, Inc. - IND/CTA Filed, 2014 15
OncoMed Pharmaceuticals, Inc. - Preclinical, 2014 16
OncoMed Pharmaceuticals, Inc. - Pipeline by Target, 2014 34
OncoMed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 35
OncoMed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 36
OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 37
OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 38
OncoMed Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 49 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify